Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Extracellular Vesicles Repair Damage in Stroke-Impaired Mice | ||
| By: PR Newswire Association LLC. - 03 Sep 2015 | Back to overview list |
|
DURHAM, N.C., Sep. 3, 2015 /PRNewswire-iReach/ -- According to a study released in the latest issue of STEM CELLS Translational Medicine, a German team of researchers discovered that extracellular vesicles (EVs), tiny membrane-enclosed structures that travel between cells, seem to work as well as adult stem cells to help the brain recover from a stroke. Photo - http://photos.prnewswire.com/prnh/20150901/262792LOGO Scientists at the University of Duisburg-Essen administered EVs, which are also referred to as exosomes, to one group of stroke-impaired mice and gave adult stem cells from bone marrow to another. After monitoring the mice for four weeks, they found that both groups experienced the same degree of neurological repair. Besides promoting brain recovery in the mice, the EVs also appeared to modulate post-stroke immune responses and provide long-term neurological protection. The study could lead to a new clinical treatment for ischemic strokes because EVs carry far fewer risks than adult stem cell transplants, team co-leaders Thorsten Doeppner, a neurologist, and Bernd Giebel, a transfusion medicine specialist, suggested. "We predict that with stringent proof-of-concept strategies, it might be possible to translate this therapy from rodents to humans, since EVs are better suited to clinical use than stem cell transplants," said Doeppner and Giebel. EVs, believed to transmit biological signals between the body's cells to direct a wide range of processes, are now under intense scientific investigation for the role they could play in cancer, infectious diseases, and neurological disorders. Although other studies have shown that administering EVs can be beneficial after a stroke, the Duisburg-Essen study is the first to supply evidence through a side-by-side analysis that EVs act as a key agent in repairing the brain. "The fact that intravenous EV delivery alone was enough to protect the post-stroke brain and help it recover highlights the clinical potential of EVs in future stroke treatment," Doeppner and Giebel said. Ten researchers from Duisburg-Essen's Department of Neurology and Institute for Transfusion Medicine collaborated on the study, which was supported by the university, Volkswagen Foundation and German Research Council. "The current research, combined with the previous demonstration that EVs are well tolerated in men, suggests the potential for using this treatment in conjunction with clot-busting therapies for treatment of stroke," said Anthony Atala, M.D., editor of STEM CELLS Translational Medicine and Director of the Wake Forest Institute for Regenerative Medicine. Article: "Extracellular Vesicles Improve Post-Stroke Neuroregeneration and Prevent Post-Ischemic Immunosuppression," Thorsten R. Doeppner, Josephine Herz, Bernd Giebel et al. (DOI: 10.5966/sctm.2015-0078). The article can be accessed at www.StemCellsTM.com. About STEM CELLS Translational Medicine: STEM CELLS Translational Medicine (SCTM) is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices. About AlphaMed Press: Established in 1983, AlphaMed Press, which has offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, is the publisher of three internationally renowned peer-reviewed journals: STEM CELLS Translational Medicine® (www.StemCellsTM.com), currently in its 4th year, is dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. STEM CELLS® (www.StemCells.com), celebrating its 33rd year, is the world's first journal devoted to this fast paced field of research. The Oncologist® (www.TheOncologist.com), which is entering its 20th year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. Media Contact: Nick Lively, AlphaMed Press, (919) 680-0011, nick.lively@alphamedpress.com News distributed by PR Newswire iReach: https://ireach.prnewswire.com SOURCE STEM CELLS Translational Medicine 
|
||
|
|
||
 | Back to overview list | |